Biosimilar sponsors in the US can decline to provide their biologics license application and manufacturing process information to innovator companies without the worry of being sued for damages under state law.
The US Court of Appeals for the Federal Circuit ruled in a Dec. 14 opinion in Amgen Inc. v. Sandoz Inc. that state law claims are preempted by the federal Biologics Price Competition and Innovation Act (BPCIA)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?